Date published: 2026-1-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

N-Dodecanoyl-NBD-ceramide trihexoside

0.0(0)
Write a reviewAsk a question

Molecular Weight:
1145
Molecular Formula:
C54H91N5O21
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

N-Dodecanoyl-NBD-ceramide trihexoside is a compound that functions as a fluorescent lipid analog in cellular and molecular studies. It is used to investigate lipid metabolism, trafficking, and signaling pathways within cells. N-Dodecanoyl-NBD-ceramide trihexoside is incorporated into cellular membranes, where its fluorescent properties allow for visualization and tracking of lipid dynamics. N-Dodecanoyl-NBD-ceramide trihexoside is particularly useful for studying lipid-protein interactions and membrane organization. Its mechanism of action involves insertion into lipid bilayers, where it can be utilized to monitor membrane dynamics and lipid trafficking.N-Dodecanoyl-NBD-ceramide trihexoside is for elucidating the roles of lipids in cellular processes. Its fluorescent properties make it a useful for studying lipid-related phenomena at the molecular and cellular levels.


N-Dodecanoyl-NBD-ceramide trihexoside References

  1. Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease.  |  Hsu, J., et al. 2011. J Control Release. 149: 323-31. PMID: 21047542
  2. Epithelial-Mesenchymal Transition in Kidney Tubular Epithelial Cells Induced by Globotriaosylsphingosine and Globotriaosylceramide.  |  Jeon, YJ., et al. 2015. PLoS One. 10: e0136442. PMID: 26291612
  3. Highly Versatile Polyelectrolyte Complexes for Improving the Enzyme Replacement Therapy of Lysosomal Storage Disorders.  |  Giannotti, MI., et al. 2016. ACS Appl Mater Interfaces. 8: 25741-25752. PMID: 27610822
  4. Upregulation of ASIC1a channels in an in vitro model of Fabry disease.  |  Castellanos, LCS., et al. 2020. Neurochem Int. 140: 104824. PMID: 32841711
  5. Extracellular vesicles from recombinant cell factories improve the activity and efficacy of enzymes defective in lysosomal storage disorders.  |  Seras-Franzoso, J., et al. 2021. J Extracell Vesicles. 10: e12058. PMID: 33738082
  6. Development of Lanzyme as the Potential Enzyme Replacement Therapy Drug for Fabry Disease.  |  Deng, M., et al. 2022. Biomolecules. 13: PMID: 36671438

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

N-Dodecanoyl-NBD-ceramide trihexoside, 100 µg

sc-360252
100 µg
$439.00

N-Dodecanoyl-NBD-ceramide trihexoside, 1 mg

sc-360252A
1 mg
$1724.00